Matthew F. Buas, PhD, MS

Associate Attending Epidemiologist

Matthew F. Buas, PhD, MS

Associate Attending Epidemiologist
Matthew F. Buas

Office Phone



PhD, University of Pennsylvania; MS, University of Washington

Current Research Interests

Dr. Buas’ primary research focus is the molecular/genetic epidemiology of esophageal adenocarcinoma (EAC) and its precursor lesion, Barrett’s esophagus (BE). His active studies investigate the role of inherited genetics in the etiology and biology of BE/EAC using a combination of statistical, computational, and experimental approaches. These include targeted and genome-wide discovery scans to identify novel genetic susceptibility loci; multi-omics informatics pipelines to prioritize single nucleotide variants based on estimated regulatory potential; and laboratory-based functional assays to validate and characterize candidate functional/causal variants, gene targets, and disease pathways. A second area of interest is the identification of novel molecular signatures of esophageal and ovarian cancers using high-throughput omics profiling technologies. The long-term translational goal of Dr. Buas’ research is to advance new strategies for prevention, risk assessment, and early detection. His work is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI).


Selected peer-reviewed publications:

  1. Ali MW, Chen J, Yan L, Wang X, Dai JY, Vaughan TL, Casey G*, Buas MF*. A risk variant for Barrett’s esophagus and esophageal adenocarcinoma at chr8p23.1 affects enhancer activity and implicates multiple gene targets. Hum Mol Genet. 2022 Jun 29;. doi: 10.1093/hmg/ddac141. [Epub ahead of print] PMID: 35766871. *Co-corresponding
  2. Chen J, Ali MW, Yan L, Dighe SG, Dai JY, Vaughan TL, Casey G*, Buas MF*. Prioritization and functional analysis of GWAS risk loci for Barrett’s esophagus and esophageal adenocarcinoma. Hum Mol Genet. 2022 Feb 3;31(3):410-422. doi: 10.1093/hmg/ddab259. PMID: 34505128; PMCID: PMC8825357. *Co-corresponding
  3. Buas MF, Drescher CW, Urban N, Li CI, Bettcher L, Hait NC, Moysich KB, Odunsi K, Raftery D, Yan L. Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass. Sci Rep. 2021 Sep 13;11(1):18156. doi: 10.1038/s41598-021-97433-x. PMID: 34518593; PMCID: PMC8438087.
  4. Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, Gharahkhani P, Palles C, Lagergren J, Fitzgerald RC, Ye W, Caldas C, Bird NC, Shaheen NJ, Bernstein L, Gammon MD, Wu AH, Hardie LJ, Pharoah PD, Liu G, Iyer P, Corley DA, Risch HA, Chow WH, Prenen H, Chegwidden L, Love S, Attwood S, Moayyedi P, MacDonald D, Harrison R, Watson P, Barr H, deCaestecker J, Tomlinson I, Jankowski J, Whiteman DC, MacGregor S, Vaughan TL, Madeleine MM. Germline variation in inflammation-related pathways and risk of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut. 2017 Oct;66(10):1739-1747. doi: 10.1136/gutjnl-2016-311622. PMID: 27486097; PMCID: PMC5296402.
  5. Gharahkhani P*, Fitzgerald RC*, Vaughan TL*, Palles C*, Gockel I*, Tomlinson I*, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RGP, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J. Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol. 2016 Oct;17(10):1363-1373. doi: 10.1016/S1470-2045(16)30240-6. PMID: 27527254; PMCID: PMC5052458. *Contributed equally

View a full listing of Matthew F. Buas’ journal articles.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Matthew F. Buas discloses the following relationships and financial interests:

  • Crane Holdings, Co.
  • IBM
  • Microsoft Corporation

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures